bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Why Earnings Season Could Be Great for bluebird bio (BLUE)
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Humana (HUM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) Q2 results are likely to reflect better revenues and membership growth.
Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Centene's (CNC) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Centene's (CNC) second-quarter results reflect robust revenues.
ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.
Anthem (ANTM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) second-quarter results are likely to reflect impressive revenues and rising membership.
Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Soleno (SLNO) to report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.
How bluebird bio (BLUE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
by Zacks Equity Research
bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
by Zacks Equity Research
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.